NCCN 2024 Annual Congress: Hematologic Malignancies™

New York, NY US
September 20, 2024 to September 21, 2024

This congress focuses on updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies to ensure optimal patient outcomes.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, PAs, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

The goal for NCCN continuing education is to enhance patient care and outcomes by improving the competence and performance of clinicians.

The goal of the NCCN 2024 Annual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:

  • Apply the current standards of oncology care and key updates in the NCCN Guidelines® to optimize the management of patients with various hematologic malignancies.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.

Learning objectives for individual sessions are viewable here.

You may also be interested in

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Updates to the Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. Clinicians would benefit from additional education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM.
Cancer Care of the LGBTQ+ Community: Nursing Perspectives
Nurses have a responsibility to understand the unique needs of the LGBTQ+ community in order to provide quality, unbiased, and holistic care. Continued professional growth in this area will allow patients to feel safe and to be an active participant in their care.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Geron
  • Ipsen Biopharmaceuticals, Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Menarini-Stemline
  • Novartis
  • Sanofi
  • Taiho Oncology, Inc.

This educational activity is supported by independent medical educational grants from:

  • AbbVie
  • ADC Therapeutics
  • GSK

Supported by independent educational grants from:

  • Daiichi Sankyo
  • Incyte Corporation
  • Rigel Pharmaceuticals, Inc.

Supported by a grant from:

  • Pfizer Inc.
Course summary
Available credit: 
  • 13.50 AAPA Category 1 CME credit
  • 13.50 AMA PRA Category 1 Credit™
  • 13.50 ANCC contact hours
    • 13.50 ANCC Pharmacology Contact Hours
  • 13.50 Participation
Course opens: 
09/21/2024
Course expires: 
01/04/2025
Event starts: 
09/20/2024 - 1:00pm EDT
Event ends: 
09/21/2024 - 4:00pm EDT
Cost:
$0.00
Add to calendar: 
New York Marriott Marquis
1535 Broadway
New York, NY 10036
United States

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Click here to download the faculty disclosures for this program.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 13.5 contact hours. This program offers 13.5 pharmacotherapeutic contact hours for nurses. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 13.5 contact hours (1.35 CEUs) of continuing education credit. UAN: JA4008196-0000-24-090-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)


This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 13.5 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, NCCN 2024 Annual Congress: Hematologic Malignancies has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine
Pathology
Radiology

Available Credit

  • 13.50 AAPA Category 1 CME credit
  • 13.50 AMA PRA Category 1 Credit™
  • 13.50 ANCC contact hours
    • 13.50 ANCC Pharmacology Contact Hours
  • 13.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

 

CE/MOC credit should be claimed for the Congress as a whole, not session by session. You may claim credit for the Congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days after the live congress.)

Pharmacists: you must complete all requirements for credit by Tuesday, November 5, 2024.

Tracking Your Session Attendance: Download the PDF here to help keep track of your session attendance. The worksheet is for your reference only and should not be returned to NCCN staff. Completion of this worksheet is not required to claim continuing education credit.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing